■Efpeglenatide,一种新型的GLP-1受体激动剂,在改善2型糖尿病(T2DM)患者的血糖控制和诱导体重减轻方面显示出希望。这项荟萃分析评估了其治疗潜力和安全性。
■在PubMed上进行了文献检索,Scopus,和CochraneCentral从成立到2023年9月。我们选择了T2DM患者,并对接受efpeglenatide和安慰剂的患者进行了鉴定和比较。评估的结果包括空腹血糖(FPG),HbA1c,体重,BMI,和心脏代谢参数。使用随机效应模型分析数据,结果以连续结果的平均差异(MD)和安全性分析的风险比(RR)表示,以及他们各自的95%置信区间。使用Cochrane偏倚风险工具进行质量评估。
■我们在分析中纳入了11项研究。Efpeglenatide显示FPG显着降低(MD=-1.53mmol/L,95%CI=[-2.86,-0.66],p<0.01),糖化血红蛋白(MD=-0.84,95%CI=[-1.08,-0.60],p<0.01),体重(MD=-2.24kg,95%CI=[-4.20,-2.00],p<0.01),和BMI(MD=-1.61kg/m2,95%CI=[-2.12,-1.09],p<0.01)。然而,efpeglenadide与胃肠道不良事件风险的中度增加相关,恶心,腹泻,和呕吐。低血糖风险无显著升高。
■Efpeglenatide显著改善糖尿病患者的血糖结果并促进体重减轻。然而,它与胃肠道系统相关的中度不良反应有关。因此,需要进一步的试验来全面评估其安全性和有效性,从而得出可靠的结论.
■
■在线版本包含补充材料,可在10.1007/s40200-024-01409-3获得。
UNASSIGNED: Efpeglenatide, a novel GLP-1 receptor agonist, has shown promise in improving glycemic control and inducing weight loss in individuals with type 2 diabetes (T2DM). This meta-analysis assessed its therapeutic potential and safety profile.
UNASSIGNED: A literature search was conducted on PubMed, SCOPUS, and Cochrane Central from inception until September 2023. We selected patients with T2DM and identified and compared those receiving efpeglenatide to placebo. Outcomes assessed included fasting plasma glucose (FPG), HbA1c, body weight, BMI, and cardiometabolic parameters. Data were analyzed using a random-effects model, with results presented as mean differences (MD) for continuous outcomes and risk ratios (RR) for safety analysis, along with their respective 95% confidence intervals. Quality assessment was conducted using the Cochrane risk of bias tool.
UNASSIGNED: We included 11 studies in our analysis. Efpeglenatide demonstrated significant reductions in FPG (MD = -1.53 mmol/L, 95% CI = [-2.86, -0.66], p < 0.01), HbA1c (MD = -0.84, 95% CI= [-1.08, -0.60], p < 0.01), body weight (MD = -2.24 kg, 95% CI = [-4.20, -2.00], p < 0.01), and BMI (MD = -1.61 kg/m2, 95% CI= [-2.12, -1.09], p < 0.01). However, efpeglenatide was associated with a moderate increase in the risk of gastrointestinal adverse events, nausea, diarrhea, and vomiting. There was a non-significant elevated risk of hypoglycemia.
UNASSIGNED: Efpeglenatide significantly improves glycemic outcomes and promotes weight loss in individuals with diabetes. However, it is associated with moderate adverse effects related to the gastrointestinal system. Thus, further trials are warranted to comprehensively assess its safety and efficacy to derive a robust conclusion.
UNASSIGNED: UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-024-01409-3.